Journal of Diabetes Research

Glucagon-Like Peptide-1 and Diabetes 2012


Publishing date
06 Jul 2012
Status
Published
Submission deadline
06 Jan 2012

1Section of Geriatric Cardiology and Medicine, Department of Cardiovascular Medicine, University of Florence and Diabetes Section, Careggi Teaching Hospital, 50141 Florence, Italy

2Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 21250, USA

3Diabetes Agency, Careggi Teaching Hospital, 50141 Florence, Italy

4Section of Endocrinology, Department of Clinical Pathophysiology, University of Florence and Careggi University Hospital, 50141 Florence, Italy


Glucagon-Like Peptide-1 and Diabetes 2012

Description

The gastrointestinal hormone glucagon-like peptide-1 (GLP-1), which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake. The response of circulating active GLP-1 concentrations after a standard meal, as well as after an oral glucose load, has been reported to be reduced in type 2 diabetic patients in comparison with healthy subjects. Available data suggest that GLP-1 plays a relevant role in the regulation of postprandial glucose metabolism in physiologic conditions. Furthermore, the impairment of GLP-1 secretion after meals could contribute to the pathogenesis of hyperglycemia in type 2 diabetes. Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the physiologic role, biologic action, and therapeutic properties of incretins and incretin-based therapies. Potential topics include, but are not limited to:

  • Recent developments in physiology of GLP-1
  • Biology of GLP-1 recent development at the experimental level
  • Advances in therapeutic potential of GLP-1 agents
  • Effects of incretin-based therapies in delaying/halting the progression of diabetes
  • Potential beneficial/detrimental actions on the cardiovascular system (or others)
  • Potential beneficial/detrimental effect on bone metabolism
  • Potential beneficial/detrimental effect on brain metabolism/function

Considering the aims of the journal, experimental studies will be particularly welcome, as well as mechanistic studies exploring special aspects of GLP-1-related therapies, with particular regard to the cardiovascular system and to microvascular complications of diabetes. Novel data on DPP-4 inhibition, with a special focus on the possible effects of DPP-4 other than GLP-1 and GIP degradation, would also be welcome.

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jdr/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

Journal of Diabetes Research
 Journal metrics
Acceptance rate31%
Submission to final decision74 days
Acceptance to publication25 days
CiteScore3.020
Impact Factor3.040
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.